ENTA investors appear pleased with ABBV’s $2.0B guidance for 2021 Mavyret sales (#msg-161451655). As has been discussed on this board ad nauseam, Mavyret will not have positive growth, but it should have a long tail.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.